<DOC>
	<DOCNO>NCT01343706</DOCNO>
	<brief_summary>The primary objective current study investigate safety tolerability BI 409306 healthy male genotyped volunteer follow oral administration single rise dos . The secondary objective : ( 1 ) explore dose proportionality BI 409306 immediate release solid oral dosage , ( 2 ) explore relative bioavailability BI 409306 administer immediate release solid oral dosage compare oral drinking solution ( 3 ) compare safety pharmacokinetic profile two different group genotyped subject .</brief_summary>
	<brief_title>Safety Tolerability Pharmacokinetic BI 409306</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Age &gt; 21 Age &lt; 50 year 3 . Body Mass Index ( BMI ) &gt; 18.5 BMI &lt; 29.9 kg/m2 Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( include limit kind seizure , stroke psychiatric disorder ) within past 6 month 6 . History relevant orthostatic hypotension , faint spell blackout . 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 9 . Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial 10 . Any laboratory value outside reference range clinical relevance 11 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) ; 12 . A history additional risk factor Torsades de point ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome )</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>